SVNS — Solvonis Therapeutics Share News
0.000.00%
Last trade - 00:00REG - Solvonis Therapeutic - Final Results
AnnouncementRCS - Solvonis Therapeutic - Appointment of Water Tower Research
AnnouncementRCS - Solvonis Therapeutic - US CNS Executive Order
AnnouncementREG - Solvonis Therapeutic - Granted U.S. Patent from PTSD Discovery Programme
AnnouncementREG - Solvonis Therapeutic - Granted U.S. Patent from PTSD Discovery Programme
AnnouncementREG - Solvonis Therapeutic - SVN-114 selected for PTSD discovery programme
AnnouncementREG - Solvonis Therapeutic - Expansion of SVN-015 into depression
AnnouncementREG - Solvonis Therapeutic - US Patent allowance for PTSD discovery programme
AnnouncementREG - Solvonis Therapeutic - Research and Development Update – Q4 2025
AnnouncementREG - Solvonis Therapeutic - SVN-015 accepted into US NIDA funded programme
AnnouncementREG - Solvonis Therapeutic - Total Voting Rights
AnnouncementREG - Solvonis Therapeutic - Corporate Structure Update and Issue of Options
AnnouncementREG - Solvonis Therapeutic - Appoints global biopharma leader Paul Carter
AnnouncementREG - Solvonis Therapeutic - Raises £1.25 Million to Accelerate Programmes
AnnouncementREG - Solvonis Therapeutic - Half-year Report
AnnouncementREG - Solvonis Therapeutic - Solvonis secures exclusive CNS collaboration
AnnouncementRCS - Solvonis Therapeutic - Media Coverage: Small Cap Idea profile
AnnouncementREG - Solvonis Therapeutic - SVN-SDN-14 PTSD - Positive pre-clinical results
AnnouncementREG - Solvonis Therapeutic - Total Voting Rights
Announcement